Il9 - interleukin 9 Gene
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 116558
Summary
Enables cytokine activity and interleukin-9 receptor binding activity. Involved in positive regulation of cell growth. Predicted to be active in extracellular space. Human ortholog(s) of this gene implicated in asthma and respiratory syncytial virus infectious disease. Orthologous to human IL9 (interleukin 9). [provided by Alliance of Genome Resources, Apr 2022]
Il9 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001105747.1 | NP_001099217.1 | interleukin-9 precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables cytokine activity |
IDA
IDA: Inferred from direct assay
|
7966560 | RGD |
| enables interleukin-9 receptor binding |
IDA
IDA: Inferred from direct assay
|
7966560 | RGD |
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| involved in positive regulation of cell growth |
IDA
IDA: Inferred from direct assay
|
7966560 | RGD |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
interleukin-9 |
|
Recombinant Il9 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P73230 | IL-9 Protein, Rat (sf9, His) | A6KAN0/NP_001099217.1 (Q19-A144) | ≥ 90%, as determined by reducing SDS-PAGE. |
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Bioactive Molecules
(4)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-Y0344D | Sodium chloride, for cell culture | Activator | 99.9% | Phase 4 |
| HY-Y0344J | Sodium chloride, for molecular biology | 99.97% | Phase 4 | |
| HY-Y0344I | Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al | 99.99% | Phase 4 | |
| HY-Y0344H | Sodium chloride, United States Pharmacopeia (USP) Reference Standard | / | Phase 4 |
Bioactive MoleculesInhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99193 | Enokizumab | 99.23% | Phase 2 | |
| HY-P991266 | SM-17 | Inhibitor | 96.98% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-161901 | BC-1293 | Inhibitor | 98.40% | Unkown |
| HY-RS06781 | IL9 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06782 | IL9R Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-174595 | Human IL9R mRNA | / | Unkown | |
| HY-174596 | Human IL9 mRNA | / | Unkown | |
| HY-RS17524 | Il9 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18766 | Il9r Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23981 | Il9 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25254 | Il9r Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990208 | Anti-Mouse IL-9 Antibody (9C1) | Inhibitor | 95.00% | Unkown |
| HY-P990206 | Anti-Mouse Jagged 2 Antibody (HMJ2-1) | Inhibitor | / | Unkown |
| HY-P990836 | Anti-IL-9 Antibody (MH9A4) | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service